Lineage Logistics Strengthens Leadership Team, Appoints New Board Member and New Chief Legal Officer
4.10.2022 21:57:00 EEST | Business Wire | Press release
Lineage Logistics, LLC (“Lineage” or the “Company”), the world’s largest and most innovative temperature-controlled industrial REIT and logistics solutions provider, today announced the appointment of Lynn Wentworth, a seasoned public board member, to its Board of Directors. Additionally, Lineage also announced the appointment of Natalie Matsler as Chief Legal Officer and Corporate Secretary. In this role, she will oversee Lineage’s global Legal, Safety & Compliance, Food Optimization and Corporate Compliance functions.
Wentworth joins Lineage’s Board of Directors at a pivotal time in the Company’s growth. She brings deep expertise in finance, technology and logistics to Lineage’s board and currently serves on the boards of Graphic Packaging (NYSE: GPK), where she chairs the Compensation & Human Capital Committee, and Benchmark Electronics (NYSE: BHE), where she chairs the Audit Committee. She is the former Chairman of CyrusOne and Cincinnati Bell and chaired the Audit & Finance Committees at both companies before her role as board chair. Before her board service, Wentworth was the Chief Financial Officer and Treasurer of BlueLinx Holdings Inc. (NYSE: BXC), a leading distributor of building products in North America. Prior to joining BlueLinx, she held numerous leadership positions with BellSouth Corporation across tax, strategic planning, investor relations, financial planning, sales and operations and was ultimately appointed CFO – Communications Group.
“As Lineage continues to grow and execute our mission of transforming the food supply chain to eliminate waste and help feed the world, we are thrilled to welcome Lynn to the board,” said Adam Forste, Co-Executive Chairman of Lineage and Co-Founder of Bay Grove. “Given her many years of experience working in areas of finance, technology and logistics, combined with her exceptional board service at a number of industry-leading corporations, we look forward to having Lynn provide a unique and valuable perspective to our board governance and our overall strategy as we continue to fuel Lineage’s global growth.”
“At such a pivotal time in the company’s history, I’m excited to join Lineage’s board of directors and to work with the leadership team as we continue to innovate and grow the global cold chain,” said Wentworth.
As the newest member of Lineage’s Executive Leadership Team, Matsler reports directly to President and CEO Greg Lehmkuhl. Most recently, she served as General Counsel of McCourt Partners, a private investment platform based in Los Angeles, Calif., where she was a member of the executive team and successfully led several projects in real estate development featuring green technology and resilient design. This is her second time working for Lineage, as she originally joined Lineage in 2014 and served in multiple legal leadership roles at the Company, including Senior Vice President and Deputy General Counsel, through April 2021. Before joining Lineage, Matsler held legal roles of increasing responsibility at Latham & Watkins LLP, Downey Savings and Loan Association, F.A. and U.S. Bank National Association. She earned a bachelor’s degree from the University of California at Los Angeles and her J.D. from the University of California at Los Angeles School of Law.
“We are thrilled to welcome Natalie back to the Lineage family,” said Greg Lehmkuhl, President and CEO of Lineage. “With a proven track record of leading, managing and advising significant projects across our global network, Natalie brings extensive experience to Lineage and will play a key role in advancing the company’s strategic initiatives. I am confident she will build upon our already-strong legal, safety and compliance teams and further contribute to Lineage’s global growth.”
“I am honored and grateful for the opportunity to return to Lineage and lead these incredibly talented teams in such a fast-growing, dynamic organization,” said Matsler. “I look forward to supporting Lineage as the company continues its global growth, all while serving Lineage’s purpose of transforming the food supply chain.”
About Lineage Logistics
Lineage Logistics is the world’s largest temperature-controlled industrial REIT and logistics solutions provider. It has a global network of over 400 strategically located facilities totaling over 2 billion cubic feet of capacity, which spans 20 countries across North America, Europe, and Asia-Pacific. Lineage’s industry-leading expertise in end-to-end logistical solutions, its unrivaled real estate network and the development and deployment of innovative technology help increase distribution efficiency, advance sustainability, minimize supply chain waste, and, most importantly, as a Visionary Partner of Feeding America, help feed the world. In recognition of the company’s leading innovations and sustainability initiatives, Lineage was a 2022 U.S. Best Managed Company, No. 3 in the 2022 CNBC Disruptor 50 list, No. 17 in the 2021 CNBC Disruptor 50 list, the No 1. Data Science company, and 23rd overall, on Fast Company’s 2019 list of The World’s Most Innovative Companies, in addition to being included on Fortune’s Change The World list in 2020. (www.lineagelogistics.com)
About Bay Grove
Bay Grove is a principal investment firm dedicated to partnering with strong management teams to invest in and build long-term platform investments. Since 2008, Bay Grove has built Lineage Logistics through acquisitions and investments completed in partnership with entrepreneurs, customers and employees. The firm has deep experience in the warehousing and logistics industry and also seeks to make investments in other attractive sectors. Bay Grove is based in San Francisco. (www.bay-grove.com)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221004006010/en/
Contact information
Lineage Logistics
Christina Wiese
734.608.1855
cwiese@lineagelogistics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
